{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:03:38Z","timestamp":1793361818031,"version":"4.5.0"},"reference-count":115,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Medicine Reviews"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.tmrv.2019.09.004","type":"journal-article","created":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T02:08:22Z","timestamp":1571710102000},"page":"256-265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics"],"prefix":"10.1016","volume":"33","author":[{"given":"Christopher J","family":"Patriquin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin H.M.","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tmrv.2019.09.004_bb0005","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/imr.12475","article-title":"Protection of host cells by complement regulators","volume":"274","author":"Schmidt","year":"2016","journal-title":"Immunol Rev"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0010","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.smim.2018.03.003","article-title":"Intracellular complement activation-an alarm raising mechanism?","volume":"38","author":"Reichhardt","year":"2018","journal-title":"Semin Immunol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0015","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrneph.2016.70","article-title":"Complement in disease: a defence system turning offensive","volume":"12","author":"Ricklin","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0020","first-page":"412","article-title":"Local release of properdin in the cellular microenvironment: role in pattern recognition and amplification of the alternative pathway of complement","volume":"3","author":"Cortes","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0025","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMoa031688","article-title":"Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria","volume":"350","author":"Hillmen","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0030","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0035","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1161\/01.CIR.0000087404.53661.F8","article-title":"Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial","volume":"108","author":"Mahaffey","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0040","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1161\/01.CIR.0000087447.12918.85","article-title":"Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in myocardial infarction treated with angioplasty (COMMA) trial","volume":"108","author":"Granger","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0045","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0050","doi-asserted-by":"crossref","unstructured":"R.A. Brodsky, N.S. Young, E. Antonioli, A.M. Risitano, H. Schrezenmeier, J. Schubert, A. Gaya, L. Coyle, C. de Castro, C.L. Fu, J.P. Maciejewski, M. Bessler, H.A. Kroon, R.P. Rother, P. Hillmen. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria, Blood 2008; 111:1840\u20131847.","DOI":"10.1182\/blood-2007-06-094136"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0055","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.12347","article-title":"Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria","volume":"162","author":"Hillmen","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0060","doi-asserted-by":"crossref","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","article-title":"Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival","volume":"117","author":"Kelly","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0065","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1182\/blood-2007-06-095646","article-title":"Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria","volume":"110","author":"Hillmen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0070","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/ajh.24278","article-title":"Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study","volume":"91","author":"Loschi","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0075","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0080","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0085","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal complement inhibitor Eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0090","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome","volume":"89","author":"Greenbaum","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0095","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0100","series-title":"N Engl J med","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","author":"Pittock","year":"2019"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0105","doi-asserted-by":"crossref","first-page":"7227","DOI":"10.1073\/pnas.0501536102","article-title":"A common haplotype in the complement regulatory gene factor H (HF1\/CFH) predisposes individuals to age-related macular degeneration","volume":"102","author":"Hageman","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0110","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00401-017-1734-6","article-title":"Bystander mechanism for complement-initiated early oligodendrocyte injury in neuromyelitis optica","volume":"134","author":"Tradtrantip","year":"2017","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0115","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/apm.12566","article-title":"Understanding the complement-mediated glomerular diseases: focus on membranoproliferative glomerulonephritis and C3 glomerulopathies","volume":"124","author":"Lionaki","year":"2016","journal-title":"APMIS"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0120","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.clim.2018.09.004","article-title":"Safety profile after prolonged C3 inhibition","volume":"197","author":"Reis","year":"2018","journal-title":"Clin Immunol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0125","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1182\/blood-2018-99-110827","volume":"132","author":"Wong","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0130","unstructured":"Achillion. Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Combination Trial with Eculizumab at The New Era of Aplastic Anemia and PNH Meeting. 2019."},{"key":"10.1016\/j.tmrv.2019.09.004_bb0135","doi-asserted-by":"crossref","first-page":"7926","DOI":"10.1073\/pnas.1820892116","article-title":"Inhibitor for the treatment of complement-mediated diseases","volume":"116","author":"Schubart","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0140","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2018-06-856930","article-title":"Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial","volume":"133","author":"Jager","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0145","unstructured":"Omeros. Omeros to Present Results from Dose-Ranging Stage of OMS721 Clinical Trial in Atypical Hemolytic Uremic Syndrome at World Congress of Nephrology. 2017."},{"key":"10.1016\/j.tmrv.2019.09.004_bb0150","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1182\/blood-2012-11-467209","article-title":"C1-esterase inhibitor concentrate rescues erythrocytes from complement-mediated destruction in autoimmune hemolytic anemia","volume":"121","author":"Wouters","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0155","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.4049\/jimmunol.1203548","article-title":"Rational engineering of a minimized immune inhibitor with unique triple-targeting properties","volume":"190","author":"Schmidt","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0160","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1182\/blood.V128.22.3891.3891","article-title":"Investigational RNAi therapeutic (ALN-CC5) targeting complement C5 for treatment of PNH and complement-mediated diseases: preliminary phase 1\/2 study results in patients with PNH","volume":"128","author":"Hill","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0165","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor Avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0170","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/ajh.25016","article-title":"Toward complement inhibition 2.0: next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria","volume":"93","author":"Risitano","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0175","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nrneph.2017.156","article-title":"The renaissance of complement therapeutics","volume":"14","author":"Ricklin","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0180","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.molimm.2018.06.008","article-title":"Developments in anti-complement therapy; from disease to clinical trial","volume":"102","author":"Harris","year":"2018","journal-title":"Mol Immunol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0185","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1053\/j.seminhematol.2018.02.002","article-title":"Expanding complement therapeutics for the treatment of paroxysmal nocturnal Hemoglobinuria","volume":"55","author":"Mastellos","year":"2018","journal-title":"Semin Hematol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0190","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3389\/fimmu.2019.00337","article-title":"Complement in thrombotic microangiopathies: unraveling Ariadne\u2019s thread into the labyrinth of complement therapeutics","volume":"10","author":"Gavriilaki","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0195","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3389\/fimmu.2019.00672","article-title":"Complement therapeutics in autoimmune disease","volume":"10","author":"Thurman","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0200","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.molimm.2019.06.018","article-title":"ANCA associated vasculitis: the journey to complement-targeted therapies","volume":"112","author":"Quintana","year":"2019","journal-title":"Mol Immunol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0205","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3389\/fimmu.2019.00329","article-title":"Complement therapeutics in the multi-organ donor: do or Don't?","volume":"10","author":"van Zanden","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0210","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3389\/fimmu.2019.01007","article-title":"The challenges and promise of complement therapeutics for ocular diseases","volume":"10","author":"Park","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0215","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.28","article-title":"Paroxysmal nocturnal haemoglobinuria","volume":"3","author":"Hill","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195909","article-title":"Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action","volume":"13","author":"Sheridan","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0225","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","article-title":"Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study","volume":"133","author":"Kulasekararaj","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0230","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","article-title":"Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study","volume":"133","author":"Lee","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0235","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40265-019-01068-2","article-title":"Ravulizumab: first global approval","volume":"79","author":"McKeage","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0240","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2018-99-112262","volume":"132","author":"Weyne","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0245","first-page":"4750","volume":"130","author":"Roeth","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0250","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/s41598-017-01087-7","article-title":"Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases","volume":"7","author":"Fukuzawa","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0255","series-title":"European Hematology Association","article-title":"RA101495, a subcutaneoulsy-administered peptide inhibitor of complement component C5, for the treatment of paroxysmal nocturnal hemoglobinuria: Phase 2 results","volume":"2018","author":"Hill","year":"2018"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0260","first-page":"4747","article-title":"Coversin, a novel C5 complement inhibitor, is safe and effective in the treatment of PNH: results of a phase II clinical trial","volume":"130","author":"Hill","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0265","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0270","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1182\/blood-2013-11-536573","article-title":"Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"123","author":"Risitano","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0275","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1586\/17474086.2014.953926","article-title":"Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape","volume":"7","author":"Mastellos","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0280","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2249.2004.02627.x","article-title":"The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation","volume":"138","author":"Harboe","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0285","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1053\/j.seminhematol.2018.05.014","article-title":"C3-mediated extravascular hemolysis in PNH on eculizumab: mechanism and clinical implications","volume":"55","author":"Notaro","year":"2018","journal-title":"Semin Hematol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0290","first-page":"2019","author":"K.A. Browett P, Lee JW, Notaro R, Brodsky R, Huang M, Geffner M, Risitano A. A Phase 2 open-label proof of concept study of the oral, small molecule Factor D inhibitor, ACH-4471, in untreated pateints with paroxysmal nocturnal hemoglobinuria (PNH). European Hematology Association","year":"2019","journal-title":"Amsterdam, The Netherlands"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0295","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1053\/j.seminhematol.2018.04.002","article-title":"Complement activation and inhibition in autoimmune hemolytic Anemia: focus on cold agglutinin disease","volume":"55","author":"Berentsen","year":"2018","journal-title":"Semin Hematol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0300","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1182\/asheducation-2018.1.382","article-title":"Autoimmune hemolytic anemia","volume":"2018","author":"Hill","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0305","first-page":"9181698","article-title":"Refractory IgG warm autoimmune hemolytic anemia treated with eculizumab: a novel application of anticomplement therapy","volume":"2016","author":"Ma","year":"2016","journal-title":"Case Rep Hematol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0310","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-226429","article-title":"Severe refractory idiopathic warm autoimmune haemolytic anaemia responsive to complement inhibition with eculizumab","volume":"11","author":"Neave","year":"2018","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0315","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/bjh.15109","article-title":"How I manage patients with cold agglutinin disease","volume":"181","author":"Berentsen","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0320","first-page":"455","article-title":"Antiphospholipid antibodies and complement activation in patients with cerebral ischemia","volume":"10","author":"Davis","year":"1992","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0325","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1160\/TH11-08-0554","article-title":"Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome","volume":"107","author":"Breen","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0330","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1182\/blood-2015-09-672139","article-title":"Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery","volume":"127","author":"Meroni","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0335","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1182\/blood-2011-02-339564","article-title":"Beta(2)-glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator","volume":"118","author":"Gropp","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0340","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3389\/fimmu.2019.00449","article-title":"Complement in the pathophysiology of the antiphospholipid syndrome","volume":"10","author":"Chaturvedi","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0345","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.tracli.2019.02.008","article-title":"Complement activation during intravascular hemolysis: implication for sickle cell disease and hemolytic transfusion reactions","volume":"26","author":"Merle","year":"2019","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0350","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1006\/clin.1994.1072","article-title":"Activation of the alternative complement pathway by red blood cells from patients with sickle cell disease","volume":"71","author":"Chudwin","year":"1994","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0355","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ajh.25384","article-title":"Critical role of C5a in sickle cell disease","volume":"94","author":"Vercellotti","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0360","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3324\/haematol.2018.198622","article-title":"Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease-modulating molecule","volume":"104","author":"Lombardi","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0365","first-page":"2014","author":"NHLBI","year":"2014","journal-title":"Evidence-Based Management of Sickle Cell Disease: Expert Panel Report"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0370","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1111\/trf.13144","article-title":"Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab","volume":"55","author":"Boonyasampant","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0375","series-title":"Transfusion","article-title":"Anti-N and anti-do(a) immunoglobulin G alloantibody-mediated delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease treated with eculizumab and HBOC-201: Case report and review of the literature","author":"Unnikrishnan","year":"2019"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0380","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/03630269.2018.1540353","article-title":"Successful outcome of hyperhemolysis in sickle cell disease following multiple lines of treatment: the role of complement inhibition","volume":"42","author":"Vlachaki","year":"2018","journal-title":"Hemoglobin"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0385","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.4049\/jimmunol.174.4.2084","article-title":"Complement inhibitor of C5 activation from the soft tick Ornithodoros moubata","volume":"174","author":"Nunn","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0390","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1053\/j.seminhematol.2018.04.003","article-title":"Complement in pathophysiology and treatment of transplant-associated thrombotic microangiopathies","volume":"55","author":"Jodele","year":"2018","journal-title":"Semin Hematol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0395","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","article-title":"Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults","volume":"124","author":"Jodele","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0400","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1182\/blood-2015-08-663435","article-title":"The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy","volume":"127","author":"Jodele","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0405","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s00277-017-3092-9","article-title":"Plasma levels of complement activation fragments C3b and sC5b-9 significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation","volume":"96","author":"Qi","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0410","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.bbmt.2018.01.009","article-title":"Early increase in complement terminal pathway activation marker sC5b-9 is predictive for the development of thrombotic Microangiopathy after stem cell transplantation","volume":"24","author":"Horvath","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0415","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/bmt.2016.253","article-title":"Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplant-associated thrombotic microangiopathy?","volume":"52","author":"Dhakal","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0420","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.bbmt.2015.10.002","article-title":"Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation","volume":"22","author":"Jodele","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0425","unstructured":"BusinessWire. Omeros Reports Significant Improvement in Overall Survival Data in OMS721-Treated Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy. 2018."},{"key":"10.1016\/j.tmrv.2019.09.004_bb0430","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1182\/bloodadvances.2016002832","article-title":"Use of the complement inhibitor Coversin to treat HSCT-associated TMA","volume":"1","author":"Goodship","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0435","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00467-015-3310-4","article-title":"C3 Glomerulopathy","volume":"32","author":"Riedl","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0440","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3389\/fimmu.2019.00362","article-title":"Therapeutic inhibition of the complement system in diseases of the central nervous system","volume":"10","author":"Carpanini","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0445","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1021\/bc060349x","article-title":"Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation","volume":"18","author":"Boado","year":"2007","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0450","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/nyas.13522","article-title":"Myasthenia gravis: the role of complement at the neuromuscular junction","volume":"1412","author":"Howard","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0455","unstructured":"RaPharma. Ra Pharmaceuticals Announces Positive Top-line Data from Phase 2 Trial of Zilucoplan in Patients with Generalized Myasthenia Gravis. 2018."},{"key":"10.1016\/j.tmrv.2019.09.004_bb0460","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/14737175.2018.1491310","article-title":"Advances in autoimmune myasthenia gravis management","volume":"18","author":"Wang","year":"2018","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0465","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106824","article-title":"Potential therapeutic benefit of C1-esterase inhibitor in neuromyelitis optica evaluated in vitro and in an experimental rat model","volume":"9","author":"Tradtrantip","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0470","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0140-6736(18)31069-9","article-title":"p. Second workshop on orphan drugs. Outrageous prices of orphan drugs: a call for collaboration","volume":"392","author":"Luzzatto","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0475","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/ejh.13176","article-title":"How we treat paroxysmal nocturnal hemoglobinuria: a consensus statement of the Canadian PNH network and review of the national registry","volume":"102","author":"Patriquin","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0480","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High risk for invasive meningococcal disease among patients receiving Eculizumab (Soliris) despite receipt of meningococcal vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0485","doi-asserted-by":"crossref","first-page":"E1558","DOI":"10.1503\/cmaj.170508","article-title":"Risks of novel therapeutics: gonococcemia in an immune-suppressed patient receiving eculizumab","volume":"189","author":"Khandelwal","year":"2017","journal-title":"CMAJ"},{"issue":"4","key":"10.1016\/j.tmrv.2019.09.004_bb0490","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/cid\/ciy958","article-title":"Disseminated gonococcal infections in patients receiving eculizumab: a case series","volume":"69","author":"Crew","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0495","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/bjh.15790","article-title":"Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis","volume":"185","author":"Socie","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0500","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.molimm.2014.06.030","article-title":"Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach","volume":"61","author":"Grumach","year":"2014","journal-title":"Mol Immunol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0505","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood-2017-05-781450","article-title":"Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults","volume":"130","author":"Konar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0510","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.molimm.2018.06.005","article-title":"Tissue-targeted complement therapeutics","volume":"102","author":"Tomlinson","year":"2018","journal-title":"Mol Immunol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0515","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.3389\/fimmu.2018.02237","article-title":"Interpretation of serological complement biomarkers in disease","volume":"9","author":"Ekdahl","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0520","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2014-03-560540","article-title":"Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab","volume":"125","author":"Peffault de Latour","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0525","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/cei.12890","article-title":"Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders","volume":"187","author":"Wehling","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0530","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0535","series-title":"Benigni","article-title":"A","volume":"V","author":"Galbusera","year":"2019"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0540","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40620-016-0288-3","article-title":"Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment","volume":"30","author":"Walle","year":"2017","journal-title":"J Nephrol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0545","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12882-019-1314-1","article-title":"Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study","volume":"20","author":"Menne","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0550","first-page":"310","article-title":"Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome","volume":"10","author":"Macia","year":"2017","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0555","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1056\/NEJMoa1502950","article-title":"Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria","volume":"373","author":"Kelly","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0560","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40620-016-0357-7","article-title":"Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab","volume":"30","author":"Asif","year":"2017","journal-title":"J Nephrol"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0565","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jval.2018.08.008","article-title":"Evaluating Canadians' values for drug coverage decision making","volume":"22","author":"Rizzardo","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.tmrv.2019.09.004_bb0570","unstructured":"Selexis. Generium Launches First Biosimilar of Eculizumab; Becomes Fifth Marketed Product Using Selexis SUREtechnology Platform. 2019."},{"key":"10.1016\/j.tmrv.2019.09.004_bb0575","unstructured":"T.J. Patel D, Yang G, Yuan X, Brodsky RA, Huang M, Podos SD. In Vitro combination studies of ACH-4471 with Eculizumab to assess a potential \"switch\" treatment approach for paroxysmal nocturnal Hemoglobinuria, Blood 2017; 120: 2198."}],"container-title":["Transfusion Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796319301324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796319301324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:19:53Z","timestamp":1760138393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887796319301324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":115,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0887796319301324"],"URL":"https:\/\/doi.org\/10.1016\/j.tmrv.2019.09.004","relation":{},"ISSN":["0887-7963"],"issn-type":[{"value":"0887-7963","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics","name":"articletitle","label":"Article Title"},{"value":"Transfusion Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tmrv.2019.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}